Efficient integration of a corrected gene into a patient's genome without mutating off-target sites is a major hurdle in gene therapy. In a paper published today in emGenome Research/em, scientists have used CRISPR/Cas genome editing technology to seamlessly and efficiently correct disease-causing mutations in cells from patients with (and) #946;-thalassemia. (and) #946;-thalassemia results from inherited DNA mutations in the hemoglobin beta (HBB) gene, resulting in reduced ...
via Medindia Health News More READ
via Medindia Health News More READ
No comments:
Post a Comment